February 10th 2011 | Alternative/buyer beware/natural, Health care system, Public policy issues, Treatment | 7 Comments
Are you paying too much for nonprescription psoriasis treatments? Many psoriasis patients are paying WAY too much for 2% coal tar and other common psoriasis treatments.
Post a comment below or email us [ info@psoriasis-cure-now.org ] with your most expensive NON-prescription meds; we’re going to start calling out these overpriced products and their doctor and nonprofit
READ THE FULL POST
January 19th 2011 | Biologics, Psoriasis Research, Treatment | 0 Comments
Even treatments that are already approved by the U.S. Food and Drug Administration (FDA) are frequently tested further in clinical trials under close medical supervision. Such trials typically offer free meds and thorough medical screening – a great deal for patients. Check out our full report on psoriasis research studies for FDA-approved treatments.
With more
READ THE FULL POST
November 1st 2010 | Psoriasis Research, Treatment, Triggers/environment | 2 Comments
A small study in Iceland found that tonsillectomy in those who tend to get psoriasis flares after strep throat infections produced reductions in psoriasis symptoms for most patients for the two-year duration of the study. As reported by Skin & Allergy News:
Tonsillectomy has beneficial clinical and immunologic effects on chronic plaque psoriasis in patients
READ THE FULL POST
October 11th 2010 | Biologics, Psoriasis Research, Side-effects of treatment, Treatment | 10 Comments
[UPDATE 1/14/2011: Abbott today announced that it has withdrawn its application with the U.S. FDA to market briakinumab (ABT-874, Ozespa). Our full analysis of Abbott's pulling its briakinumab application is here. Our original, unedited post concerning the Phase Three trials is below.]
You know that buzz about Centocor Ortho Biotech’s biologic Stelara (ustekinumab),
READ THE FULL POST
October 7th 2010 | Biologics, Psoriasis Research, Treatment | 0 Comments
New data on Stelara (ustekinumab) has been presented at a European scientific meeting, and it shows Stelara performing well for most patients in the clinical trial, even after 2 years and 10 months of use. The company’s press release is here.
Some background on the study the data came from: Patients who weighed less
READ THE FULL POST
August 19th 2010 | Patient Stories, Treatment | 0 Comments
LeAnn Rimes, our favorite singer with psoriasis, appeared on national TV recently (on America’s Got Talent), wearing…a bikini. We’re not sure if that’s a great public service message about psoriasis, but it sure is a good one for her psoriasis treatment! We are thrilled that her treatment appears to be working.
But it got
READ THE FULL POST
August 16th 2010 | Treatment, UV/phototherapy | 11 Comments
Psoriasis patients have a new treatment option with Levia, a hand-held unit intended for administering ultraviolet UVB light at home. This device, recently cleared for use by the U.S. Food and Drug Administration (FDA), targets UV light directly at psoriatic lesions, sparing healthy skin from exposure, a feature that Levia’s developer, Lerner Medical Devices, terms
READ THE FULL POST
August 15th 2010 | Biologics, Psoriasis Research, Treatment | 2 Comments
Even before it received U.S. Food and Drug Administration (FDA) approval in September 2009, Stelara (ustekinumab) had considerable buzz in the psoriasis community. Imagine a treatment that (after two initial doses) you take just four times a year! But the early buzz was based on 12 week, and later 40 week, studies.
READ THE FULL POST
August 11th 2010 | Biologics, Patient Stories, Treatment, psoriatic arthritis | 0 Comments
The golf world was stunned yesterday by the news that superstar Phil Mickelson has been battling psoriatic arthritis this summer. He announced in a press conference that a severe flare of psoriatic arthritis had left him in a state where he “couldn’t move.” Read our full report on Phil Mickelson’s psoriatic arthritis.
August 8th 2010 | Psoriasis Research, Treatment | 0 Comments
The makers of voclosporin, an experimental drug being studied as a possible alternative to cyclosporin for psoriasis, organ transplant, eye disease and other uses, faced a setback last week as the U.S. Food and Drug Administration (FDA) asked for an additional Phase Three study of the drug’s use in uveitis, an eye disorder. The
READ THE FULL POST
